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Poster Session I 37myeloma (MM). While most of the pts relapse after ASCT with
a median time to progression (TTP) of 2 years, there is a significant
heterogeneity in the duration of response. It has been hypothesized
that the effect of high dose alkylator therapy used for conditioning
may have a dual effect on the MMcells as well as marrow microen-
vironment. It is also known that hematopoiesis, especially thrombo-
poiesis, depends to some extent on signals form the marrow
microenvironment. We examined if there was any relationship be-
tween delayed platelet engraftment and outcome after ASCT.
Methods:We examined the outcomes in a group of pts undergoing
ASCT for MM at our institution to compare the response duration
to platelet engraftment kinetics. We studied 687 pts undergoing
ASCTwith melphalan conditioning followed by PB stem cells.Re-
sults: Among the 687 pts undergoing ASCT, 200 (29%) achieved
a platelet count of 50,000 by day 21 (early group) and the rest
achieved this level after 21 days or never engrafted (late group).
The TTP) among the late group was 24.8 mos (95% CI; 19.6, 30)
vs. 16.8 mos (95% CI; 15.1, 18.6) for the late group (p\ 0.001).
Pts in the late engraftment group weremore likely to achieve a com-
plete response compared to the early group; 39% vs. 30%, p5 0.02.
In a multivariate analysis examining factors predicting for longer
TTP after ASCT, delayed platelet engraftment was independent
of ASCT within 12 months of diagnosis, CR with ASCT, absence
of cytogenetic abnormalities, B2M\3.5 mg/L and a plasma cell la-
beling index\1% at the time of ASCT.Conclusions: In this study,
we have demonstrated for the first time a relationship between de-
layed platelet engraftment after ASCT and the duration of response
following ASCT. This intriguing finding raises several hypotheses.
It is possible that the delayed platelet engraftment is a marker of
marrow microenvironment dysfunction secondary to high dose
therapy, given the role of marrow microenvironment on thrombo-
poiesis. It is possible that this is a surrogatemarker for the biological
effectiveness of the melphalan dose, which can affect the other cells
in the marrow microenvironment as well. It is likely a reflection of
the marrow microenvironment dependence on the myeloma cells
for its survival. These findings should be confirmed in other larger
patient groups.95
NEULASTA AS GROWTH FACTOR SUPPORT AFTER AUTOLOGOUS
STEM CELL TRANSPLANTATION
Rice, R.D.1, Baker, L.B.2,Moskowitz, C.H.3 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer Cen-
ter, New York, NY; 3Memorial Sloan-Kettering Cancer Center, New
York, NY.
Significance and Background: High-dose therapy and autolo-
gous stem cell transplant (HDT/SCT) is complicated by an ex-
pected period of pancytopenia, through which the patient must be
supported.With the introduction of granulocyte colony stimulating
factors in the early 1990s, this period was shortened. Still, pro-
longed neutropenia puts the patient at risk of infection which may
have serious consequences and may be fatal. Pegfilgrastim, a pegy-
lated version of filgrastim, has been used as post-HDT/SCTgrowth
factor support in a small number of European centers, but its use in
the United States for this indication has not been widely adopted.
Purpose: To evaluate the use of Neulasta (pegfilgrastim) as
post-transplant colony stimulating factor support compared to
Neupogen (filgrastim) for adult autologous SCT patients. Inter-
ventions: Between February and September 2007, we treated 56
patients who were undergoing HDT/SCT as standard of care
with pegfilgrastim 6 mg subcutaneously once on day 1 1. Patient
and treatment characteristics are detailed in the table below. We
compared this sample to an historical control sample of 190 patients
in 2005 who were treated with filgrastim (flat weight-based dosing)
starting on either day1 5 or day 1 1 and continuing until engraft-
ment. Evaluation: Mean day to neutrophil engraftment . 500 K/
mcL for the pegfilgrastim sample was 9.6 days (median 9 days),
compared to the historical control sample (mean 10.49 days; median
10 days). AverageWholesale Price (AWP) is not dramatically differ-
ent ($3,557 for Neulasta  1; $3090 for Neupogen 480 mcg  7
daily doses). One patient had a slow ANC engraftment (day 1
22). No patient had a delayed hospital discharge due to red bloodcell or platelet transfusion requirements. One patient had a pro-
tracted hospital course due to infectious complications; two patients
required transfer to the intensive care unit, one for sepsis, one for
infection and myocardial infarction. There were no observations
of clinically significant post-engraftment fevers or engraftment syn-
drome. Treatment related mortality in this cohort was 0%.Discus-
sion: Neulasta is equally efficacious in neutrophil recovery as
Neupogen post autologous HDT/SCT. It has the advantage of re-
quiring only one injection for the patient and appears to potentiate
a reduction in overall hospital length of stay.Patient/Treatment CharacteristicsGender
Male 33
Female 23Median Age 55
Diagnosis
Diffuse Large B Cell
Lymphoma8Mantle Cell
Lymphoma8Peripheral T Cell
Lymphoma3Hodgkin Lymphoma 6
Multiple myeloma 27
AL Amyloidosis 4Conditioning
BEAM 18
CBV 4
MELPHALAN 31
TBI/CY/ETOP 396
INCIDENCE AND FACTORS INFLUENCING STEM CELL MOBILIZATION IN
PATIENTS WITH NON-HODGKIN’S LYMPHOMA (NHL) AND HODGKIN’S
DISEASE (HD)
Popat, U., Saliba, R., Ahlawat, S., Okoroji, G.-J., Alousi, A.,
Anderlini, P., Andersson, B., de Lima, M., Jones, R., Kebriaei, P.,
Korbling, M., Nieto, Y., Qazilbash, M., Shpall, E.J., Khouri, I.,
Giralt, S., Champlin, R., Hosing, C. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Autologous transplantation from peripheral blood
stem cells is an important curative therapeutic option in patients
with chemosensitive Hodgkin’s (HD) and non-Hodgkin’s Lym-
phoma (NHL), but is not available for patients who fail to mobilize.
In this study we wished to estimate the incidence of mobilization
failure in lymphoma patients seen atM.D. AndersonCancer Center
and identify predictive factors. Methods: We retrospectively re-
viewed charts of all patients referred in the calendar years 2003
and 2004 with NHL and HD, in whom peripheral blood stem
cell collection was attempted. Mobilization failure was defined as
inability to collect 2  106 CD341 cells/Kg. Predictors of mobili-
zation failure were evaluated using logistic regression analysis in-
cluding type of mobilization chemotherapy, age, sex, number of
prior chemotherapies, bone marrow cellularity, platelet count,
white blood cell count, prior bone marrow involvement with malig-
nancy, and prior radiation. Results: During the study period, 206
patients, 130 males and 76 females with a median age of 48 years
(range 10–81 years) were deemed eligible for autologous transplant
and underwent stem cell mobilization. Sixty five patients had HD
and 141 patients had NHL. Mobilization regimens were as follows:
Ifosfamide and Etoposide 147, Cyclophosphamide 14, other che-
motherapeutic regimens 26, and G-CSF alone 19. Twenty-nine
of 206 (14%) patients failed to mobilize stem cells. The majority
of these cases (26/29) were NHL patients (odds ratio for NHL ver-
sus HD: 4.7; p5 0.01). On univariate analysis, use of G-CSF alone
as opposed to chemotherapy, platelet count\150K/ul, and bone
marrow cellularity\ 30% were the only significant predictors of
mobilization failure in NHL. In view of small number of patients
multivariate analysis was not possible. However, a low platelet
38 Poster Session Icount (\150K/ul) was the only significant predictor when the anal-
ysis was restricted to NHL patients mobilized with chemotherapy
(odds ratio 8.9, p\ 0.001). Conclusions: A significant proportion
(18%) of patients with NHL fails to mobilize stem cells. Use of fil-
grastrim without chemotherapy was associated with high failure
rate, but this needs to be confirmed in a larger comparative study.
For patients who were mobilized with chemotherapy, low platelet
count is the most significant predictive factor.
Univariate Analysis in Patients with NHL
N N Failed % Fail OR1 95% CI2 pPlatelet Count
\150 K 34 14 41
$150 K 107 12 11 0.2 0.1–0.4 \0.001Cellularity
\30% 44 13 30 2.7 1.1–6.5 0.02
$30% 97 13 13Regimen
Ifos/VP16 96 12 13
G-CSF alone 13 8 62 11.2 3.1–40 \0.001
Cyclophosphamide 14 3 21 1.9 0.5–7.8 0.4Other 18 3 17 1.4 0.3–5.6 0.61Odds Ratio.
2Confidence Interval.97
POSITRON EMISSION TOMOGRAPHY IDENTIFIES A DIFFERENTIAL
PATTERN OF BONE MARROW FDG UPTAKE IN ‘‘POOR’’ AND ‘‘GOOD’’
PERIPHERAL STEM CELL MOBILIZERS
Marcacci, G.1, Caraco`, C.2, D’Arena, G.1, Aloj, L.2, Corazzelli, G.1,
Frigeri, F.1, Lastoria, S.2, Pinto, A.1 1National Cancer Institute ‘‘Fon-
daz. Pascale’’, Naples, Italy; 2National Cancer Institute ‘‘Fondaz. Pas-
cale’’, Naples, Italy.
The use of prophylactic G-CSF is associated to the increase of
bone marrow (BM) fluorodeoxyglucose (FdG) uptake as detected
by Positron Emission Tomography (PET). In contrast, no data is
available as to changes in BM FdG-uptake during peripheral blood
stem cell (PBSC) mobilization. This study was aimed at investigat-
ing patterns of BMFdGuptake duringmobilization as quantified by
Standardized Uptake Value (SUV) determinations. We also evalu-
ated whether PET scanning may turn of value for identifying good
and poor mobilizers. To our knowledge this is the first PET-based
study in this setting. Methods Seventeen patients(pts)(M/F 5 10/
7), median age 51 yrs (r 28–65), with relapsed lymphoma (NHL/
HD5 13/4) without BM involvement, were accrued after informed
consent. Baseline PET was obtained at relapse, before salvage ther-
apy and anyCSF administration. After salvage regimes pts weremo-
bilized by VRL/CTX or ARA-C; G-CSF (10 mg/kg/d) was given
from day 16 through apheresis. PET scans were obtained on day
19 or 110 (after nadir with a WBC . 1000/ml). SUVmax and av-
erage (avg) were measured (whole lumbar spine and bilateral iliac
regions) and compared to SUV of the same BM regions at baseline
PET. The aim was to calculate a BM specific D-SUV (mobilizing vs
steady-state D-SUV) for each single patient. ResultsTwelve pts mo-
bilized PBSC (median CD34 peak 39.99/ml, r 23.28–280.58/ml; me-
dian CD34 in the harvest 3.3 106/Kg, r 2.1–12.5) while 5 pts were
poor mobilizers (median CD34 peak 10.9/ml, r 7.5–14.1/ml). In the
group of good mobilizers, apheresis was performed at CD34 peak
(day 111,114), with a median of 1 apheresis/pt (r 1–2). Unexpect-
edly, effective mobilization was associated with a low BM uptake of
FdG: median BM D-SUVmax and D-SUVavg of 2.0 (r 1.0–3.8) and
2.3 (r 0.9–3.9), respectively. In contrast, poor mobilizers displayed
a median D-SUVmax and D-SUVavg of 4.7 (r 2.4–12.8) and 5.9
(r 4.1–14.2), respectively.
Conclusions: While FdG-BM uptake usually increases upon
CSF administration, our results suggest that PBSC mobilization
may be associated with a more complex metabolic pattern of BM
as detected by PET. We documented that, 48 to 72 hrs beforeCD34 peak, poor mobilizers display a higher FdG-BM uptake
(D-SUV . 3) as compared to good mobilizers (D-SUV\ 3). These
preliminary results indicate that BM PETmay represent a new tool
for early identification of poor mobilizers allowing a timely modifi-
cation of the mobilization strategy to possibly rescue the procedure.98
RADIO-IMMUNOTHERAPY FOR LOW GRADE NON-HODGKIN’S LYM-
PHOMAMAY IMPAIR THE ABILITY TOMOBILIZE AUTOLOGOUS PERIPH-
ERAL BLOOD STEM CELLS
Raptis, A., Mapara,M., Bilodeau, A., Hornyak,M., Agha,M.E. UPMC
Cancer Centers/University of PittsburghMedical Center, Pittsburgh, PA.
High dose chemotherapy and autologous stem cell transplanta-
tion (ASCT) is a proven effective treatment modality for patients
with relapsed non-Hodgkin’s lymphoma. Radioimmunotherapy
(RIT) with 90Y-ibritumomab tiuxetan has been shown to be useful
in patients with relapsedNHL, but is now being used in the upfront
setting for patients with low gradeNHL, as some protocols now of-
fer abbreviated chemotherapy courses followed by RIT. As patients
relapse high dose therapy and ASCT become a valuable option but
the effect of RIT on the stem cell collection becomes an important
issue. We report four patients with follicular NHL who relapsed
within 6–8 months after RIT were treated with salvage chemother-
apy then mobilized with Cyclophosphamide and G-CSF. Two pa-
tients were heavily pre-treated for multiple relapses, but two had
only one relapse following upfront RIT. Only 2/4 patients mobi-
lized successfully, but with low yield. One of the patients developed
secondary leukemia, 6 months after ASCT. Surprisingly, the mobi-
lization failure patients were young, not heavily treated (had 6–7 cy-
cles of chemotherapy including the upfront and salvage therapy), no
exposure to external beam radiotherapy, but had heavy tumor bur-
den at initial presentation. Our results suggest that mobilization
failure following RIT is much higher that would have been pre-
dicted. Caution should be exercised when offering RIT to patients
with bulky disease low grade lymphoma as part of the upfront ther-
apy, as rapid relapsesmay not be salvageable with high dose therapy,
given the high rate of mobilization failure even in patients who are
not heavily treated. The long term safety of RIT andmyelodysplasia
in such patients is also an important concern, given the short inter-
val of tAML in our patient.99
PREDICTORS OF OUTCOME OF MANTLE CELL LYMPHOMA IN PATIENTS
WITH PROGRESSIVE DISEASE FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT)
Al-Farsi, K., Nagy, T., Keating, A., Crump, M., Kuruvilla, J. Princess
Margaret Hospital, Toronto, ON, Canada.
Introduction: Mantle Cell Lymphoma (MCL) is a subgroup of
malignant lymphomas that is considered incurable with conven-
tional therapy.While ASCT has improved progression free survival
(PFS), relapse remains a major issue. For patients (pts) who relapse
after ASCT, there is little information on the predictors of outcome
and optimal treatment strategy. We reviewed pts with progressive
disease following ASCT in an attempt to identify predictors of sub-
sequent outcome.Method:We retrospectively reviewed our com-
puterized database and charts of pts undergoing ASCT from May
1987 - Jul 2006. Of 47 pts, 21 relapsed after ASCT; 20 had adequate
data on subsequent therapy and were analyzed for factors influenc-
ing progression free survival (PFS) and overall survival (OS) using
Kaplan-Meier and Cox-Proportional Hazards analyses. Results:
Pt characteristics: At relapse post-ASCT, median age was: 56 years
(range 40–69). Stage 3 or 4: 16. High LDH: 8. Disease status of
ASCT: CR1/PR1 5 9, .CR1/PR1 5 11. IPI scores: low (n 5 9),
low-intermediate (n 5 8), high-intermediate (n 5 2) and high
(n 5 1). FLIPI scores: low (n 5 10), intermediate (n 5 4) and
high (n 5 6). Seven had bone marrow involvement, 3 had involve-
ment of peripheral blood and 5 had splenomegaly. Eighteen pts re-
ceived subsequent treatment: R-FCM: 4, Rituximab: 1, Radiation
